Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
- DOI
- 10.1016/j.jtocrr.2023.100562
- Published
- 2023 Oct
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2023.100562,
title = {Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.},
author = {Lau SCM and Perdrizet K and Fung AS and Mata DGMM and Weiss J and Holzapfel N and Liu G and Bradbury PA and Shepherd FA and Sacher AG and Feilotter H and Sheffield B and Hwang D and Tsao MS and Cheng S and Cheema P and Leighl NB},
year = {2023},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2023.100562},
url = {https://doi.org/10.1016/j.jtocrr.2023.100562}
}RIS
TY - JOUR TI - Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies. AU - Lau SCM AU - Perdrizet K AU - Fung AS AU - Mata DGMM AU - Weiss J AU - Holzapfel N AU - Liu G AU - Bradbury PA AU - Shepherd FA AU - Sacher AG AU - Feilotter H AU - Sheffield B AU - Hwang D AU - Tsao MS AU - Cheng S AU - Cheema P AU - Leighl NB PY - 2023 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2023.100562 UR - https://doi.org/10.1016/j.jtocrr.2023.100562 ER -
APA
SCM, L., K, P., AS, F., DGMM, M., J, W., N, H., G, L., PA, B., FA, S., AG, S., H, F., B, S., D, H., MS, T., S, C., P, C., & NB, L. (2023). Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2023.100562
Source records
- pubmed · retrieved 2026-09-26T19:42:07.729Z